Optimising Antibiotic Use for Paediatric Lower Respiratory Tract Infections in Africa
Optimising Antibiotic Use for Young African Children Hospitalised With Lower Respiratory Tract Infections: the Role of Biomarkers, Clinical Severity Scoring and Clinician Attitudes
- Lower Respiratory Tract Infection (LRTI)
- Pneumonia
- Bronchopneumonia
- Bronchiolitis
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- University of Witwatersrand, South Africa
- Enrolment target
- 400
- Started
- 27 May 2026
- Main results due
- 26 May 2027
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- Ages 2 months to 24 months.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Children between the ages of 2-24 months * Clinician diagnosis of lower respiratory tract infection (LRTI) Exclusion Criteria: * Transferred from other hospitals with more than 24 hours of hospitalisation * Hospitalisation within the preceding 30 days
What this study is about
In the sponsor’s own words, from the registry.
Lower respiratory tract infections (LRTIs) remain a leading cause of hospitalisation and death among young children in Africa. Although viral infections account for a substantial proportion of LRTIs, antibiotics are frequently prescribed because distinguishing between viral and bacterial infections can be challenging. This contributes to unnecessary antibiotic exposure and the rising global public health challenge of antimicrobial resistance.
This pragmatic, unblinded randomised controlled study will evaluate whether the combination of point-of-care (POC) C-reactive protein (CRP) testing and the PREPARE clinical severity score can safely reduce antibiotic use among children aged 2 to 24 months hospitalised with LRTI at Chris Hani Baragwanath Academic Hospital (CHBAH), South Africa. Participants will be randomly assigned in a 1:1 ratio to either the intervention group, where antibiotic decisions are guided by serial POC CRP measurements and repeated PREPARE severity assessments, or a control group receiving routine clinical care.
The primary objective of the study is to compare antibiotic use during hospitalisation between the intervention and control groups. Secondary objectives are to evaluate the safety of this approach by comparing mortality, hospital readmission within 28 days, adverse events, need for invasive ventilation, duration of hospitalisation, and other clinical outcomes between study groups. In addition, the study will compare healthcare-related costs, including antibiotic expenditure and costs associated with hospitalisation.
A parallel mixed-methods component will explore clinician attitudes, beliefs, and determinants of antibiotic prescribing for children hospitalised with LRTI using surveys, focus groups discussions, and individual interviews informed by the Theoretical Domains Framework (TDF). Findings will help identify behavioural and system-level factors that influence antibiotic prescribing and inform future antimicrobial stewardship interventions.
This study aims to generate evidence on whether biomarker-guided and risk-stratified care can safely optimise antibiotic use among young African children hospitalised with LRTI while improving antimicrobial stewardship and reducing healthcare costs.
Study sites(1)
Chris Hani Baragwanath Academic Hospital
Johannesburg, Gauteng, South Africa
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07841691. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me